Bristol-Myers Squibb Co (NYSE:BMY) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 57,526,799 shares, a growth of 18.9% from the January 15th total of 48,401,111 shares. Approximately 3.5% of the shares of the company are sold short. Based on an average trading volume of 15,761,533 shares, the short-interest ratio is currently 3.6 days.
BMY opened at $50.98 on Thursday. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41. Bristol-Myers Squibb has a twelve month low of $44.30 and a twelve month high of $70.05. The stock has a market cap of $82.10 billion, a P/E ratio of 12.81, a price-to-earnings-growth ratio of 1.60 and a beta of 0.83.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 50.03%. The company had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. During the same quarter in the previous year, the business posted $0.68 EPS. The firm’s revenue was up 9.6% on a year-over-year basis. Equities analysts predict that Bristol-Myers Squibb will post 4.16 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, February 1st. Shareholders of record on Friday, January 4th were issued a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 3.22%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. The ex-dividend date was Thursday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is 41.21%.
Several hedge funds have recently made changes to their positions in the company. Riverview Trust Co bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at about $33,000. Portfolio Solutions LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $37,000. Gantzert Investment Co. LLC ADV bought a new position in Bristol-Myers Squibb in the 4th quarter worth approximately $39,000. 1 North Wealth Services LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $42,000. Finally, Berman Capital Advisors LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at $63,000. Institutional investors and hedge funds own 73.19% of the company’s stock.
A number of equities research analysts have recently commented on BMY shares. William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, October 22nd. Citigroup downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $62.00 to $57.00 in a report on Monday, October 22nd. ValuEngine lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Friday, October 19th. Credit Suisse Group restated a “hold” rating and issued a $59.00 price objective on shares of Bristol-Myers Squibb in a report on Thursday, December 13th. Finally, BMO Capital Markets increased their price objective on Bristol-Myers Squibb from $55.00 to $58.00 and gave the company a “market perform” rating in a research report on Friday, November 16th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $60.21.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Macon Daily and is the sole property of of Macon Daily. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://macondaily.com/2019/02/14/bristol-myers-squibb-co-bmy-short-interest-up-18-9-in-january.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
See Also: What is the Rule of 72?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.